The materials you are responsible for are listed below. I would of course encourage you to browse through the other topics under Drug Therapies, including the 3 drug approvals in 2017 and 2018 (Safinamide/Xadago and two new extended-release formulations of amantadine).
Physiological Basis of Parkinson’s
Drug Therapies
| Intro to levodopa |
| Why must patients take levodopa so frequently? |
| What are the major side effects of levodopa? |
| Intro to MAO-B inhibitors |
| Intro to dopamine agonists |
| Nuplazid for Parkinson’s psychosis |
| Droxidopa for orthostatic hypotension |
